Neil Clark, chief executive of Destiny Pharma plc (LON:DEST), spoke to Proactive's Andrew Scott following the release last week of a new 5 year action plan by the UK government to tackle the problem of antibiotic resistance.
Clark says the recent awarding of up to £1.6mln to them of new grant funding is validation of the company’s strategy.
He also talks through positive results they've announced from a second phase 1 clinical study of its XF-73 nasal gel.
Price: 115.5 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
Destiny Pharma's (LON:DES) Neil Clark (CEO) pitches to investors at the Proactive One2One live virtual forum. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its...
Mining
Prev article
